M. Kieny

Negotiating public-health intellectual property licensing agreements to increase access to health technologies: an insider’s story
202316 citationsauthor #4
Reboot biomedical R&D in the global public interest
202231 citationsauthor #7
A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project
20229 citationsauthor #29
SARS-CoV-2 variants and ending the COVID-19 pandemic
2021453 citationsauthor #4
Research priorities to increase vaccination coverage in Europe (EU joint action on vaccination).
202110 citationsauthor #4
The Early Development of the Vaccinia–Rabies Recombinant Vaccine Raboral®
20210 citationsauthor #2
Vaccination anti COVID-19 pour les personnes souffrant de cancer : un impératif médical et éthique
20212 citationsauthor #3
The WHO we want
202014 citationsauthor #2
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
20202,295 citationsauthor #9
Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination
202010 citationsauthor #23
French research strategy to tackle antimicrobial resistance.
20203 citationsauthor #8
Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013–2016 West Africa Ebola outbreak in Guinea
202018 citationsauthor #22
Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline.
201960 citationsauthor #6
Patent pooling to increase access to essential medicines
201939 citationsauthor #8
Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report
201918 citationsauthor #13
What if communities held the solutions for universal health coverage?
201912 citationsauthor #2
A roadmap for sustainably governing the global antimicrobial commons.
201916 citationsauthor #7
Lessons learned from Ebola Vaccine R&D during a public health emergency
201816 citationsauthor #1
Questionable efficacy of the rVSV-ZEBOV Ebola vaccine - Authors' reply.
20187 citationsauthor #4
Systematic Analysis of Evidence and Sound Expert Assessment: Two Enablers of Evidence‐Based Decision‐Making in Health
20184 citationsauthor #1
Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability.
201818 citationsauthor #6
Delivering Quality Health Services: A Global Imperative for Universal Health Coverage
2018566 citationsauthor #1
Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model
201822 citationsauthor #14
World Health Organization Methodology to Prioritize Emerging Infectious Diseases in Need of Research and Development
201899 citationsauthor #5
From vaccines to global health to vaccines
20180 citationsauthor #1
Detectable Vesicular Stomatitis Virus (VSV)–Specific Humoral and Cellular Immune Responses Following VSV–Ebola Virus Vaccination in Humans
201837 citationsauthor #32
Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial
201762 citationsauthor #19
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.
20174,510 citationsauthor #45
Systems science for universal health coverage
20176 citationsauthor #2
Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report
201785 citationsauthor #24
Perspectives on sexual transmission of Ebola virus: complementarity between research and public health intervention
20170 citationsauthor #2
Seasonal vaccines – Critical path to pandemic influenza response
201722 citationsauthor #3
Medication Without Harm: WHO's Third Global Patient Safety Challenge.
2017442 citationsauthor #4
Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization☆
201771 citationsauthor #35
Next Generation Inactivated Poliovirus Vaccine: The Future Has Arrived.
20179 citationsauthor #3
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)
2017878 citationsauthor #22
Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
2017118 citationsauthor #27
WHO R&D Blueprint: a global coordination mechanism for R&D preparedness.
201733 citationsauthor #1
The third global patient safety challenge: tackling medication-related harm.
201797 citationsauthor #4
Strengthening health systems for universal health coverage and sustainable development
2017245 citationsauthor #1
One attack on a health worker is one too many.
20171 citationsauthor #1
Towards access 2030.
20174 citationsauthor #2
Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial
201726 citationsauthor #18
On a path to accelerate access to Ebola vaccines: The WHO's research and development efforts during the 2014-2016 Ebola epidemic in West Africa.
201650 citationsauthor #5
Global platform to inform investments for health R&D.
20167 citationsauthor #1
Priority-setting for achieving universal health coverage
2016149 citationsauthor #9
A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation
201656 citationsauthor #6
Data sharing in public health emergencies: a call to researchers
201665 citationsauthor #4
Public health: Use open data to curb Zika virus
20163 citationsauthor #1
The Zika Challenge.
201668 citationsauthor #2
Best practices for sharing information through data platforms: establishing the principles
20169 citationsauthor #5
The need for global R&D coordination for infectious diseases with epidemic potential
201629 citationsauthor #1
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.
2016145 citationsauthor #22
Developing Global Norms for Sharing Data and Results during Public Health Emergencies
2016162 citationsauthor #6
H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
201635 citationsauthor #10
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.
2016407 citationsauthor #54
Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial
2016202 citationsauthor #14
Developing a vaccine against Zika
20167 citationsauthor #5
Regulatory policy for research and development of vaccines for public health emergencies
20168 citationsauthor #1
Cost–effectiveness thresholds: pros and cons
2016646 citationsauthor #6
Rationale for WHO's New Position Calling for Prompt Reporting and Public Disclosure of Interventional Clinical Trial Results
2015122 citationsauthor #4
Building the Human Vaccines Project: strategic management recommendations and summary report of the 15–16 July 2014 business workshop
20155 citationsauthor #2
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
2015264 citationsauthor #20
Tough decisions on essential medicines in 2015
201524 citationsauthor #7
Beyond Ebola: a new agenda for resilient health systems.
2015112 citationsauthor #1
Honouring the value of people in public health: a different kind of p-value
201510 citationsauthor #4
Informing the establishment of the WHO Global Observatory on Health Research and Development: a call for papers
201512 citationsauthor #3
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
2015708 citationsauthor #27
The Evolution of the Meningitis Vaccine Project
201538 citationsauthor #3
Monitoring Progress towards Universal Health Coverage at Country and Global Levels
2014445 citationsauthor #5
The international Ebola emergency.
2014232 citationsauthor #5
Monitoring progress towards universal health coverage: recent developments.
20142 citationsauthor #3
Health policy and systems research: building momentum and community
20146 citationsauthor #4
Ebola vaccine--an urgent international priority.
2014120 citationsauthor #6
Health-system resilience: reflections on the Ebola crisis in western Africa
2014215 citationsauthor #1
The 2014 Ebola outbreak: ethical use of unregistered interventions
201421 citationsauthor #2
Human resources for universal health coverage: from evidence to policy and action.
201324 citationsauthor #2
Global production capacity of seasonal influenza vaccine in 2011.
201369 citationsauthor #2
Safety of the Recombinant Cholera Toxin B Subunit, Killed Whole-Cell (rBS-WC) Oral Cholera Vaccine in Pregnancy
201293 citationsauthor #18
Health Systems Global, the new international society for health systems research.
20123 citationsauthor #2
Putting health policy and systems research on the map.
20125 citationsauthor #3
2009 Pandemic influenza A virus subtype H1N1 vaccination in Africa--successes and challenges.
201226 citationsauthor #5
Research agenda for mass gatherings: a call to action
201271 citationsauthor #6
Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study.
2012127 citationsauthor #12
Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets.
201117 citationsauthor #6
WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer.
201196 citationsauthor #7
Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.
2011137 citationsauthor #4
Complex systems analysis: towards holistic approaches to health systems planning and policy.
201146 citationsauthor #2
Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets.
201089 citationsauthor #2
Reducing empiricism in malaria vaccine design.
201018 citationsauthor #2
Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010.
201032 citationsauthor #5
Report of the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009.
201021 citationsauthor #7
The 2009 A (H1N1) influenza virus pandemic: A review.
2010508 citationsauthor #4
WHO supports fair access to influenza A (H1N1) vaccine.
20096 citationsauthor #1
Correction: Development of a Mouse Monoclonal Antibody Cocktail for Post-exposure Rabies Prophylaxis in Humans
200920 citationsauthor #13
European Union conference on poverty-related diseases research.
20095 citationsauthor #4
A vaccine against malaria: a substantial step forward.
20094 citationsauthor #3
New influenza A(H1N1) vaccine: How ready are we for large-scale production?
20094 citationsauthor #3
Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits.
200933 citationsauthor #2
Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials.
20095 citationsauthor #4

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT